FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer
- 2 August 2017
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (401)
Abstract
Folate-conjugated microRNAs are specifically taken up by tumor cells and inhibit tumor progression in mice.Keywords
Funding Information
- National Cancer Institute (award301056, R00CA178091)
- National Cancer Institute (award301057, P30CA023168)
- Indiana Clinical and Translational Sciences Institute (award301059)
- Endocyte (award301058, 200766)
This publication has 64 references indexed in Scilit:
- Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative SplicingMolecular Pharmaceutics, 2012
- Nucleic Acid–Gold Nanoparticle Conjugates as Mimics of microRNASmall, 2011
- Strain-Promoted “Click” Chemistry for Terminal Labeling of DNABioconjugate Chemistry, 2011
- Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer TherapyMolecular Therapy, 2010
- MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesisNature Medicine, 2010
- Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug ReleaseBioconjugate Chemistry, 2010
- Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor modelNature Biotechnology, 2010
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- Folate receptor alpha as a tumor target in epithelial ovarian cancerGynecologic Oncology, 2008
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005